Unsealed Bayer Documents In Lawsuits Show Yasmin Poses Significant Risk of Deep Vein Thrombosis and Pulmonary Embolism
As we reported in a previous blog, tomorrow the FDA will be considering safety findings on Yasmin and Yaz, but will not be armed with some alarming data Bayer apparently withheld from U.S. regulators. The former head of the FDA, David Kessler, stated in a document unsealed yesterday by the MDL court in Illinois, that […]
Bayer Attacks Philadelphia County Mass Tort Program Seeking to Scatter Yaz Victims’ Cases Across The Country to Gain Advantage in Yaz Litigation
In an effort to gain an advantage in the Yaz, Yasmin and Ocella personal injury litigation, Bayer launched an assault on the Philadelphia County Mass Tort program and the experienced judges who administer it. Bayer recently filed a King’s Bench petition asking the Pennsylvania Supreme Court to hold that the Philadelphia County Mass Tort program […]
Important Details About FDA’s Dec. 8, 2011 Meeting About Birth Control Such As Yaz and Yasmin
The FDA’s joint meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee will be held on December 8, 2011, from 8 a.m. to 5 p.m. The location is The Marriott Inn and Conference Center, University of Maryland University College, The Ballroom, 3501 University Blvd. East, Adelphi, […]
FDA Posts Questions and Answers About Increased Risks of Blood Clots With Birth Control Like Yaz and Yasmin
The FDA has posted questions and answers that provide a safety overview of Yaz and Yasmin. The link to the questions and answers is: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm273039.htm The FDA provides answers to the following questions: Q1. What is drospirenone? Q2. Which birth control pills (oral contraceptives) contain drospirenone? Q3. What is a venous thromboembolic event (VTE)? Q4. […]
FDA To Hold Meeting on December 8, 2011 About Safety of Yaz and Yasmin
On December 8, 2011, the FDA is holding a meeting of the Reproductive Health Drugs Advisory Committee and the Drug and Safety Risk Management Committee to discuss the risk of blood clots in drugs such as Yaz and Yasmin that contain drospirenone. This is on the heels of the release of the FDA’s study showing […]
FDA Landmark Study on the risks of Birth control such as Yaz, Yasmin, Ocella, Nuvaring and Ortho Evra
Breaking news was released from the FDA this morning concerning a landmark study of the risk of arterial and venous cardiovascular complications caused by Yaz, Yasmin and Ocella. Until now, there was limited data available regarding the risk of venus thromboembolism (VTE) (deep venous thrombosis [DVT] and pulmonary embolism [PE]) in combined hormonal contraceptives (CHCs), […]
